Methylphenidate: Difference between revisions

| classes          = Psychostimulant, CNS stimulant, NDRI

| pregnancy        = Category C

| intro            = '''Methylphenidate''' is a piperidine-derivative central nervous system stimulant and the most widely prescribed medicine for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor — distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.

| pharmacokinetics  = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver — not by cytochrome P450 enzymes — to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated drug interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.

| pharmacodynamics  = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters — it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

| dosing            = '''Ritalin IR (children ≥6 y, adults):''' Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses.

| adverse          = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease (FDA warning)

* '''Tics''' — methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication

* '''Dependence and misuse''' — Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant

* '''Growth suppression''' — modest reduction in height/weight velocity in chronically-treated children

* '''Priapism''' — rare but documented; FDA warning, especially in adolescents

* '''Peripheral vasculopathy''' — Raynaud-like phenomenon, rare digital ischemia

* '''Lowered seizure threshold''' — caution in epilepsy

* '''Lassitude / "crash"''' on withdrawal — fatigue, dysphoria, rebound hyperactivity

* '''Stereotyped behaviors''' — rare at therapeutic doses

* '''Skin reactions''' — chemical leukoderma (permanent depigmentation) at Daytrana patch application sites

| contraindications = * Hypersensitivity to methylphenidate

* Concurrent MAOI use, or within 14 days of MAOI discontinuation

* Symptomatic cardiovascular disease, advanced atherosclerosis, moderate–severe hypertension, recent MI

* '''Relative:''' Tourette syndrome / tic disorders, history of substance use disorder, bipolar disorder, psychotic disorders, structural cardiac abnormalities (consider cardiology evaluation)

| interactions      = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid) — hypertensive crisis risk; contraindicated

* '''Tricyclic antidepressants''' — methylphenidate may elevate TCA plasma levels; additive cardiovascular effects

* '''Warfarin / coumarins''' — methylphenidate may elevate INR

* '''Phenytoin, phenobarbital, primidone''' — methylphenidate may elevate anticonvulsant levels

* '''Antihypertensives''' — methylphenidate's pressor effect may partially antagonize

* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants) — additive cardiovascular effects

* '''Antipsychotics''' — pharmacologic antagonism (each may partially block the other's effects)

* '''Alcohol''' — may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism

* '''Caffeine''' — additive stimulant and anxiogenic effects

Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s — a clinical advantage over amphetamine when polypharmacy is a concern.

| pregnancy_details = Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies — interpretation complicated by confounding by indication. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.

* Periodically reassess continued need; consider drug holidays in children to assess ongoing benefit and minimize growth-velocity effects

* '''Concerta:''' the osmotic tablet shell will appear intact in stool — this is normal and does not mean the medicine wasn't absorbed.

* Do not combine with significant alcohol or other stimulants.

* Do not share or sell — Schedule II controlled substance; serious legal and clinical consequences.

* Plan for the "crash" when the dose wears off — particularly with IR formulations late afternoon.

| references        =